Wenzhou Kangning Hospital
Market Cap
HK$2.2b
Last Updated
2021/01/23 10:29 UTC
Data Sources
Company Financials +
Executive Summary
Wenzhou Kangning Hospital Co., Ltd. operates and manages a network of healthcare facilities in the People’s Republic of China. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with moderate growth potential.
Share Price & News
How has Wenzhou Kangning Hospital's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2120 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 2120's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
16.7%
2120
12.1%
HK Healthcare
3.5%
HK Market
1 Year Return
25.1%
2120
-7.6%
HK Healthcare
15.1%
HK Market
Return vs Industry: 2120 exceeded the Hong Kong Healthcare industry which returned -7.6% over the past year.
Return vs Market: 2120 exceeded the Hong Kong Market which returned 15.1% over the past year.
Shareholder returns
| 2120 | Industry | Market | |
|---|---|---|---|
| 7 Day | 16.7% | 12.1% | 3.5% |
| 30 Day | 10.2% | 12.4% | 12.7% |
| 90 Day | 30.6% | 25.5% | 18.1% |
| 1 Year | 25.1%25.1% | -5.1%-7.6% | 19.7%15.1% |
| 3 Year | -24.5%-25.1% | -41.6%-45.3% | -5.1%-15.1% |
| 5 Year | -20.3%-22.2% | -24.0%-31.3% | 65.1%37.0% |
Long-Term Price Volatility Vs. Market
How volatile is Wenzhou Kangning Hospital's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
Will Wenzhou Kangning Hospital (HKG:2120) Multiply In Value Going Forward?4 weeks ago | Simply Wall St
Should You Use Wenzhou Kangning Hospital's (HKG:2120) Statutory Earnings To Analyse It?1 month ago | Simply Wall St
If You Had Bought Wenzhou Kangning Hospital's (HKG:2120) Shares Five Years Ago You Would Be Down 42%Valuation
Is Wenzhou Kangning Hospital undervalued compared to its fair value and its price relative to the market?
44.94x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 2120 (HK$30.7) is trading above our estimate of fair value (HK$6.87)
Significantly Below Fair Value: 2120 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 2120 is poor value based on its PE Ratio (44.9x) compared to the HK Healthcare industry average (21.4x).
PE vs Market: 2120 is poor value based on its PE Ratio (44.9x) compared to the Hong Kong market (11.9x).
Price to Earnings Growth Ratio
PEG Ratio: 2120 is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: 2120's PB Ratio (1.6x) is in line with the HK Healthcare industry average.
Next Steps
Future Growth
How is Wenzhou Kangning Hospital forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
22.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2120's forecast earnings growth (22.7% per year) is above the savings rate (1.5%).
Earnings vs Market: 2120's earnings (22.7% per year) are forecast to grow faster than the Hong Kong market (21.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 2120's revenue (12.1% per year) is forecast to grow slower than the Hong Kong market (14.4% per year).
High Growth Revenue: 2120's revenue (12.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2120's Return on Equity is forecast to be low in 3 years time (9.7%).
Next Steps
Past Performance
How has Wenzhou Kangning Hospital performed over the past 5 years?
2.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2120 has a large one-off loss of CN¥26.7M impacting its June 30 2020 financial results.
Growing Profit Margin: 2120's current net profit margins (4.4%) are lower than last year (11.8%).
Past Earnings Growth Analysis
Earnings Trend: 2120's earnings have grown by 2.7% per year over the past 5 years.
Accelerating Growth: 2120's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2120 had negative earnings growth (-54%) over the past year, making it difficult to compare to the Healthcare industry average (-9.1%).
Return on Equity
High ROE: 2120's Return on Equity (1.6%) is considered low.
Next Steps
Financial Health
How is Wenzhou Kangning Hospital's financial position?
Financial Position Analysis
Short Term Liabilities: 2120's short term assets (CN¥691.0M) exceed its short term liabilities (CN¥635.6M).
Long Term Liabilities: 2120's short term assets (CN¥691.0M) exceed its long term liabilities (CN¥324.8M).
Debt to Equity History and Analysis
Debt Level: 2120's debt to equity ratio (36.2%) is considered satisfactory.
Reducing Debt: 2120's debt to equity ratio has increased from 0.3% to 36.2% over the past 5 years.
Debt Coverage: 2120's debt is well covered by operating cash flow (26.2%).
Interest Coverage: 2120's interest payments on its debt are well covered by EBIT (3.1x coverage).
Balance Sheet
Next Steps
Dividend
What is Wenzhou Kangning Hospital current dividend yield, its reliability and sustainability?
1.21%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2120's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2120's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2120's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2120's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 2120 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2120's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.3yrs
Average management tenure
CEO
Lianyue Wang (51 yo)
9.33yrs
Tenure
CN¥437,986
Compensation
Ms. Lianyue Wang serves as General Manager at Wenzhou Kangning Hospital Co., Ltd. Since September 2011, and has been its Executive Director since September 22, 2014 were she is primarily responsible for th...
CEO Compensation Analysis
Compensation vs Market: Lianyue's total compensation ($USD67.57K) is below average for companies of similar size in the Hong Kong market ($USD303.71K).
Compensation vs Earnings: Lianyue's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.33yrs | CN¥539.19k | 25.44% CN¥ 563.4m | |
| GM & Executive Director | 9.33yrs | CN¥437.99k | 5.26% CN¥ 116.5m | |
| CFO & Executive Director | 6.33yrs | CN¥320.67k | 5.95% CN¥ 131.8m | |
| Vice GM & Joint Company Secretary | no data | no data | no data | |
| Deputy General Manager | 6.5yrs | no data | no data | |
| Vice General Manager | 6.33yrs | no data | no data | |
| Vice General Manager | 6.33yrs | no data | no data | |
| Vice General Manager | 6.33yrs | no data | no data | |
| Vice General Manager | 5.83yrs | no data | no data | |
| Vice General Manager | no data | no data | no data | |
| Joint Company Secretary | 5.83yrs | no data | no data |
6.3yrs
Average Tenure
50yo
Average Age
Experienced Management: 2120's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.33yrs | CN¥539.19k | 25.44% CN¥ 563.4m | |
| GM & Executive Director | 9.33yrs | CN¥437.99k | 5.26% CN¥ 116.5m | |
| CFO & Executive Director | 6.33yrs | CN¥320.67k | 5.95% CN¥ 131.8m | |
| Non-Executive Director | 3.58yrs | no data | no data | |
| Independent Non Executive Director | 0.58yr | no data | no data | |
| Non-Executive Director | 5.75yrs | no data | no data | |
| Chairman of the Supervisory Committee | 6.33yrs | CN¥52.00k | no data | |
| Supervisor | 6.33yrs | no data | no data | |
| Supervisor | 6.33yrs | CN¥38.00k | no data | |
| Independent Supervisor | 3.58yrs | no data | no data | |
| Independent Non Executive Director | 0.58yr | no data | no data | |
| Independent Non Executive Director | 0.58yr | no data | no data |
6.0yrs
Average Tenure
51yo
Average Age
Experienced Board: 2120's board of directors are considered experienced (6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Wenzhou Kangning Hospital Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Wenzhou Kangning Hospital Co., Ltd.
- Ticker: 2120
- Exchange: SEHK
- Founded: 1996
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: HK$2.215b
- Shares outstanding: 72.14m
- Website: https://www.knhosp.cn
Number of Employees
Location
- Wenzhou Kangning Hospital Co., Ltd.
- No.1 Shengjin Road
- Huanglong Residential District
- Wenzhou
- Zhejiang Province
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 2120 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Nov 2015 |
| 4WK | DB (Deutsche Boerse AG) | Yes | Foreign Shares-Foreign Listed | DE | EUR | Nov 2015 |
Biography
Wenzhou Kangning Hospital Co., Ltd. operates and manages a network of healthcare facilities in the People’s Republic of China. The company operates in two segments, Medical Service and Property Development...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/23 10:29 |
| End of Day Share Price | 2021/01/22 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.